Crossmark

Imaging Aβ and tau in early stage Alzheimer’s disease with [18F]AV45 and [18F]AV1451

Crossref DOI link: https://doi.org/10.1186/s13550-018-0371-y

Published Online: 2018-03-02

Published Print: 2018-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

,

Firouzian, Azadeh http://orcid.org/0000-0001-5424-0489
Whittington, Alex

Searle, Graham E.

Koychev, Ivan

Zamboni, Giovanna

Lovestone, Simon

Gunn, Roger N.
Funding

Funding for this research was provided by:

GlaxoSmithKline foundation

Dementia Platform UK

Medical Research Council UK
License Information

Text and Data Mining valid from 2018-03-02
More Information

Article History

Received: 29 November 2017

Accepted: 19 February 2018

First Online: 2 March 2018

Ethics approval and consent to participate

: All procedures performed in this study were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.All subjects participating in this study have signed an informed consent form.

: The manuscript has been seen and approved by all authors for submission to EJNMMI Research.

: The authors declare that they have no competing interests.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.